<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">861399</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2022.861399</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Natural Products as a Novel Therapeutic Strategy for NLRP3&#x20;Inflammasome-Mediated Gout</article-title>
<alt-title alt-title-type="left-running-head">Lee et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Strategy for NLRP3 Inflammasome-Mediated Gout</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Jun Ho</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1656586/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Hyuk Soon</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1414697/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Jun-Ho</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yang</surname>
<given-names>Gabsik</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1640549/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kim</surname>
<given-names>Hong Jun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>College of Korea Medicine</institution>, <institution>Woosuk University</institution>, <addr-line>Jeonju-si</addr-line>, <country>South Korea</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Biomedical Sciences</institution>, <institution>College of Natural Science and Department of Health Sciences</institution>, <institution>The Graduate School of Dong-A University</institution>, <addr-line>Busan</addr-line>, <country>South Korea</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1582089/overview">Gi-Sang Bae</ext-link>, Wonkwang University, South Korea</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/768530/overview">Dong-Sung Lee</ext-link>, Chosun University, South Korea</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1656645/overview">Dong-Gu Kim</ext-link>, Jeonbuk National University, South Korea</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Gabsik Yang, <email>yanggs@woosuk.ac.kr</email>; Hong Jun Kim, <email>kimboncho@woosuk.ac.kr</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>03</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>861399</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>01</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>02</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Lee, Kim, Lee, Yang and Kim.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Lee, Kim, Lee, Yang and Kim</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Gout is the most common form of inflammatory arthritis. It occurs when monosodium urate crystals (MSU) are deposited within joints due to hyperuricemia and persistent elevations of serum uric acid levels. Traditional gout treatment such as urate-lowering therapy is difficult to continue for a long period of time due to the risk of side effects. Recent studies have shown that the modulation of MSU-induced inflammatory responses is dependent on the inflammatory cytokine IL-1&#x3b2;, which has a central role in a chain of processes involving multiple cytokines and mediators. In this regard, the NLRP3 inflammasome is known to play a crucial part and thus has been proposed as a novel target in the treatment for gout. However, the biochemical mechanism for NLRP3 inflammasome activation has not yet been clearly elucidated. Therefore, this report can provide an overview of natural extractions targeted to prevent or treat NLRP3&#x20;inflammasome-mediated gout in the MSU-induced gout model. In addition, the research and development of such natural products are suggested as a potential strategy in the treatment of&#x20;gout.</p>
</abstract>
<kwd-group>
<kwd>gout</kwd>
<kwd>monosodium urate (MSU)</kwd>
<kwd>NLRP3 inflammasome</kwd>
<kwd>interleukin-1&#x3b2;</kwd>
<kwd>natural producct</kwd>
</kwd-group>
<contract-sponsor id="cn001">Korea Health Industry Development Institute<named-content content-type="fundref-id">10.13039/501100003710</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">National Research Foundation of Korea<named-content content-type="fundref-id">10.13039/501100003725</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Gout is the most common form of inflammatory arthritis affecting adults. It is a chronic disease caused by monosodium urate (MSU) crystal deposition. A recent study reported the range from prevalence as &#x3c;1%&#x2013;6.8% and the incidence as 0.58&#x2013;2.89 per 1,000&#x20;person-years (<xref ref-type="bibr" rid="B6">Dehlin et&#x20;al., 2020</xref>). Gout typically presents as an acute, self-limited inflammatory monoarthritis affecting the joints of the lower extremities. Elevated serum uric acid level (hyperuricemia) is a major risk factor for MSU crystal deposition and the onset of gout. MSU crystals are preferentially deposited in the joints and periarticular structures. In particular, gout usually presents as acute, excruciating pain, and inflammatory arthritis in the first metatarsophalangeal joint, metatarsophagus, and knee area (<xref ref-type="bibr" rid="B47">Taylor et&#x20;al., 2015</xref>). Gout flares usually resolve naturally within 7&#x2013;10&#xa0;days and are interspersed between asymptomatic &#x2018;intercritical phases.&#x2019; Over time, prolonged hyperuricemia can cause more frequent and severe redness that also affects the upper extremities and several joints (<xref ref-type="bibr" rid="B12">Gutman, 1973</xref>). In Traditional Korean Medicine, terminology such as bibing, lijiefeng, baihufeng, and tongfeng are used to describe disorders with comparable characteristics to gout. Among these, the &#x2018;tongfeng&#x2019; notion dates all the way back to the Jin and Yuan eras. Throughout the Ming and Qing dynasties, different theories on the etiology, prevention, and treatment of tongfeng were suggested (<xref ref-type="bibr" rid="B4">Cho and Jung, 2015</xref>). Acupuncture with bee venom has anti-inflammatory and analgesic properties, and it has long been utilized as a traditional Korean therapy for musculoskeletal problems, particularly gout arthritis (<xref ref-type="bibr" rid="B11">Goo et&#x20;al., 2021</xref>).</p>
<p>Currently, in gout patients, pharmacological agents that reduce purine break-down (i.e.,&#x20;xanthine oxidase inhibitors (XOIs)) or drugs that increase urinary excretion of uric acid (i.e.,&#x20;uric acid preparations) are generally administered as urate-lowering therapy to decrease uric acid levels. Allopurinol is the oldest XOI currently in use, and more recently Febuxostat, which has a more selective and less complex dosing regimen than allopurinol, is also being administered to patients. Additionally, marketed uric acid excretion agents that increase uric acid excretion primarily through urine include probenecid, sulfinpyrazone and benzbromarone, as well as the recently approved lesinurad (<xref ref-type="bibr" rid="B5">Dalbeth et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B37">Saag et&#x20;al., 2017</xref>). However, XOIs have disadvantages such as multiple dose regimens, unsuitability for use in patients with severe chronic kidney disease, and increased risk of renal calculus formation. For this reason, researchers have been exploring alternative treatment strategies such as those involving the use of natural products.</p>
<p>On the other hand, pathologically, joints affected by gout flare are characterized by distinct neutrophil infiltration in both the synovial tissue and synovial fluid (<xref ref-type="bibr" rid="B21">Landis and Haskard, 2001</xref>). Recent studies have shown that interleukin-1&#x3b2; (IL-1&#x3b2;) is a major regulatory inflammatory cytokine of gout, promoting neutrophil influx into the synovial membrane and joint fluid, which is a pathological hallmark of acute inflammatory attacks (<xref ref-type="bibr" rid="B42">Silvestre et&#x20;al., 2020</xref>). Strong evidence for the role of IL-1&#x3b2; in gout-related pain and inflammation is provided in animal and human studies. In a rat gout model, after injection of MSU into the mouse ankle joint, inflammation was significantly reduced in both IL-1 receptor-deficient mice and wild-type mice treated with the IL-1 inhibitor IL1 trap (rilonacept) (<xref ref-type="bibr" rid="B30">Martin et&#x20;al., 2009</xref>; <xref ref-type="bibr" rid="B48">Torres et&#x20;al., 2009</xref>). Therefore, it supports the argument of the pivotal role of IL-1&#x3b2; in the pathogenesis of&#x20;gout.</p>
<p>In this review, we present background information on gout and the activation of NLR family pyrin domain containing 3 (NLRP3) inflammasome. We also provide research information on natural extracts with NLRP3 inflammasome regulation that have been identified in animal models of MSU-induced gout within the recent 5&#x20;years.</p>
</sec>
<sec id="s2">
<title>Mechanism of NLRP3 Inflammasome</title>
<p>The NLRP3 inflammasome is the most recently studied inflammatory regulatory complex (<xref ref-type="bibr" rid="B19">Lamkanfi and Dixit, 2012</xref>; <xref ref-type="bibr" rid="B45">Sutterwala et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B8">Elliott and Sutterwala, 2015</xref>; <xref ref-type="bibr" rid="B13">He et&#x20;al., 2016a</xref>; <xref ref-type="bibr" rid="B46">Swanson et&#x20;al., 2019</xref>). It is activated by numerous risk-related molecular patterns, including bacterial cell wall components, bacterial RNA or the bacteria themselves, and damage-related molecular patterns, such as free fatty acids, contributing to the pathology of inflammatory diseases. Despite various studies over a long period of time, the mechanism of NLRP3 inflammasome activation is still unclear. However, it is clearly known that NLRP3 inflammasome activation requires two signaling steps provided by several exogenous and endogenous activators. The first signal (priming signal) is nuclear factor kappa B (NF-&#x3ba;B)-dependent transcription of NLRP3 and pro-IL-1 which is triggered by the binding of lipopolysaccharide (LPS) to the Toll-like receptor (TLR) four ligand receptor (<xref ref-type="bibr" rid="B2">Bauernfeind et&#x20;al., 2009</xref>; <xref ref-type="bibr" rid="B35">Mu&#xf1;oz-Planillo et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B20">Lamkanfi and Dixit, 2014</xref>). The signal then promotes the expression of inflammasome components, including NLRP3, procaspase-1, and pro-IL-1&#x3b2;. The first signal is initiated by TLR4 and then transduced by related adapter molecules, including myeloid differentiation factor 88 (MyD88), IRAK1, and IRAK4, without the requirement for new protein synthesis (<xref ref-type="bibr" rid="B18">Juliana et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B9">Fernandes-Alnemri et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B25">Lin et&#x20;al., 2014</xref>). The priming signal establish NLRP3 to form inflammasome assembly from degradation by licensing the proteins to form the correct morphology for self-oligomerization and interaction with ASC, through various post-translational modifications including ubiquitylation, deubiquitination, phosphorylation, and sumoylation to NLRP3 (<xref ref-type="bibr" rid="B40">Shim and Lee, 2018</xref>; <xref ref-type="bibr" rid="B38">Seok et&#x20;al., 2020</xref>). The second signal (activation signal) involved in the assembly and activation of the NLRP3 complex (the activation signal) is induced by extracellular adenosine triphosphate (ATP), certain bacterial toxins, and various types of crystalline and particulate matter. This signal then produces active cleaved caspa-se-1. When macrophages are activated by NLRP3 activators as part of a second signal, NLRP3 undergoes oligomerization through homologous NACHT domain interactions, which recruit PYD domains to interact with PYDs in ASCs that trigger ASC fibrillar binding. Next, ASC aggregates recruit CARDs and interact with the CARD domain of procaspase-1 to promote caspase-1 activation and subsequent polymerization of ASC fibrils to the ASC spec (<xref ref-type="bibr" rid="B32">Masumoto et&#x20;al., 1999</xref>; <xref ref-type="bibr" rid="B28">Lu et&#x20;al., 2014</xref>). Clustered procaspase-1 self-cleaves and activates in the form of activated caspase-1, which cleaves precursors of IL-1&#x3b2; and IL-18 to produce activated forms of IL-1&#x3b2; and IL-18 (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>), causing an inflammatory response and pyroptosis. GSDMD activated by caspase-1 and -11 forms GSDMD pores in the cell membrane and secretes IL-1beta matured by caspase-1 along with calcium influx (<xref ref-type="bibr" rid="B49">Tsuchiya et&#x20;al., 2021</xref>). In this process, post-translational modifications of NLRP3, such as phosphorylation or deubiquitination, are required for the assembly and activation of the NLRP3 inflammasome (second signal) (<xref ref-type="bibr" rid="B18">Juliana et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B27">Lopez-Castejon et&#x20;al., 2013</xref>). In addition, potassium efflux is also a major upstream signaling event for NLRP3 inflammasome activation. Most NLRP3 stimuli is known that can cause the outflow of potassium from cells whereas the inhibition of potassium efflux by high extracellular potassium concentration can block most stimulus-induced NLRP3 inflammasome activation. Recent study demonstrate that Nek7 is an essential protein that acts downstream of potassium efflux to mediate NLRP3 inflammasome oligomerization and activation via structural formation of Nek7-NLRP3 binding (<xref ref-type="bibr" rid="B14">He et&#x20;al., 2016b</xref>; <xref ref-type="bibr" rid="B39">Sharif et&#x20;al., 2019</xref>). However, the exact mechanism by which NLRP3 inflammasome assembly is promoted is still not clearly known. When activation of NLRP3 is triggered, the formation of ASC spec can be considered as an upstream indication of NLRP3 activation (<xref ref-type="bibr" rid="B44">Stutz et&#x20;al., 2013</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Schematic structure of the acute gout inflammation. Mechanism of NLRP3 inflammasome activation in acute gout inflammation with potential intervention of natural products.</p>
</caption>
<graphic xlink:href="fphar-13-861399-g001.tif"/>
</fig>
</sec>
<sec id="s3">
<title>Role of NLRP3 Inflammasome in Gout</title>
<p>The pathological hallmark of gout attacks is known as neutrophil influx into the synovium and joint fluid (<xref ref-type="bibr" rid="B21">Landis and Haskard, 2001</xref>). However, neutrophil does not exist in normal joints, and the interaction between MSU and resident joint cells, which are mainly synovial lining cells, is known to trigger neutrophil influx due to MSU precipitation in the joint. Recent studies show that mononuclear phagocytes play a central role in the initial response to MSU precipitation. When monocyte cells were exposed to MSU, secretion of inflammatory cytokines increased, especially IL-1&#x3b2;, indicating that phagocytosis of MSU crystals was centrally mediated (<xref ref-type="bibr" rid="B52">Yagnik et&#x20;al., 2000</xref>; <xref ref-type="bibr" rid="B22">Landis et&#x20;al., 2002</xref>). Accordingly, Martinon et&#x20;al. demonstrated that the NLRP3 inflammasome is important for sensing MSU deposition and the subsequent innate immune response (<xref ref-type="bibr" rid="B31">Martinon et&#x20;al., 2006</xref>). Macrophages from mice lacking various components of the inflammasome, including caspase-1, ASC and NLRP3, were unable to activate IL-1&#x3b2; in response to MSU stimulation. Notably, these mice also showed impaired neutrophil influx after intraperitoneal MSU injection, demonstrating that the NLRP3 inflammasome is an important link between the well-established causal stimulation of gout and the subsequent pathological features of acute gout attacks (<xref ref-type="bibr" rid="B31">Martinon et&#x20;al., 2006</xref>; <xref ref-type="bibr" rid="B1">Amaral et&#x20;al., 2012</xref>). In addition to intracellular NLRP3 receptors, TLR2 and TLR4 receptors may also play a role in the innate immune response to MSU deposition (<xref ref-type="bibr" rid="B26">Liu-Bryan et&#x20;al., 2005</xref>). Macrophages isolated from TLR2&#x2212;/&#x2212; and TLR4&#x2212;/&#x2212; mice showed abnormal uptake of MSU crystals and decreased production of inflammatory cytokines, suggesting that TLR is essential for MSU crystal-induced inflammation.</p>
<p>Although much progress has been made in elucidating the biological pathways that mediate gout attacks, the precise mechanism by which endocytosed MSU crystals activate the NLRP3 inflammasome remains unclear. A recent study of the biological mechanism supporting the association between excessive food intake and the onset of gout demonstrated a synergistic relationship between free fatty acids (FFA) and MSU for IL-1&#x3b2; activation (<xref ref-type="bibr" rid="B17">Joosten et&#x20;al., 2010</xref>). In this study, MSU crystals alone were unable to induce IL-1&#x3b2; release in peripheral blood mononuclear cells (PBMCs) isolated from healthy subjects, whereas large amounts of active IL-1&#x3b2; were detected in the presence of FFA. Notably, IL-1&#x3b2; release following MSU and FFA injection was significantly reduced in caspase-1 and ASC deficient mice, but not in NLRP3 gene deficient mice. In addition, another research suggested that TLR2 and TLR4 are nonessential for the innate immune response to MSU crystals in the peritoneal model of acute gout (<xref ref-type="bibr" rid="B26">Liu-Bryan et&#x20;al., 2005</xref>). However, it can also be considered that the response to MSU stimulation through different mechanisms occurrs in cells of different tissues.</p>
<p>Although pathologically it has been firmly established that the activation of the NLRP3 inflammasome and IL-1&#x3b2; is important in the pathogenesis of gout, the interactive mechanism between MSU and cells has not been clearly elucidated. NLRP3 is a signal that induces ATP and potassium efflux through K&#x2b; channels such as P2X7 or toxins such as nigericin (<xref ref-type="bibr" rid="B10">Franchi et&#x20;al., 2007</xref>; <xref ref-type="bibr" rid="B36">P&#xe9;trilli et&#x20;al., 2007</xref>). Also, previous studies have reported that reactive oxygen species (ROS) production is also involved in NLRP3 inflammasome activation in response to MSU (<xref ref-type="bibr" rid="B3">Cassel et&#x20;al., 2008</xref>; <xref ref-type="bibr" rid="B7">Dostert et&#x20;al., 2008</xref>). Therefore, further studies on the precise signaling mechanism of the NLRP3 inflammasome and its response to MSU crystals deposition are necessary.</p>
</sec>
<sec id="s4">
<title>Natural Extract Treatment Studies for NLRP3 Inflammasome Regulation in Gout</title>
<p>Recently, many studies have demonstrated the disease improvement effects of natural extractions for the treatment of gout through the regulation of NLRP3 inflammasome assembly. In this report, we present an overview of studies regarding NLRP3&#x20;inflammasome-based therapeutic development of natural extractions for gout within the recent 5&#xa0;years (<xref ref-type="table" rid="T1">Table&#x20;1</xref>; <xref ref-type="fig" rid="F1">Figure&#x20;1</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Studies regarding natural extracts targeting NLRP3 inflammasome in&#x20;gout.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Origin of extraction</th>
<th align="center">Experimental model</th>
<th align="center">Mode of action and target signal</th>
<th align="center">Ref</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">
<italic>Mollugo pentaphylla</italic> L. (MP)</td>
<td align="left">C57BL6 mice &#x2b; MSU</td>
<td align="left">&#x2193; Inflammatory paw edema and pain, TNF-&#x3b1;, IL-1&#x3b2;, NF-&#x3ba;B, NLRP3, ASC, Caspase-1</td>
<td align="left">
<xref ref-type="bibr" rid="B24">Lee et&#x20;al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">
<italic>Cinnamomum burmanni</italic> (Nees and T.Nees) Blume (CC)</td>
<td align="left">C57BL6 mice &#x2b; MSU</td>
<td rowspan="2" align="left">&#x2193; LPS-induced sepsis, neutrophils recruitment, IL-1&#x3b2;, ASC oligomerization</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B41">Shin et&#x20;al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">BMDM &#x2b; LPS</td>
</tr>
<tr>
<td rowspan="2" align="left">
<italic>Actinidia arguta</italic> (Siebold and Zucc.) Planch. ex Miq. (AA)</td>
<td align="left">C57BL6 mice &#x2b; MSU</td>
<td rowspan="2" align="left">&#x2193; IL-1&#x3b2;, NLRP3, neutrophils recruitment</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B15">Heo et&#x20;al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">BMDM &#x2b; LPS</td>
</tr>
<tr>
<td rowspan="4" align="left">Taiwanese green propolis (TGP)</td>
<td align="left">C57BL6 mice &#x2b; MSU</td>
<td rowspan="4" align="left">&#x2193; Pro IL-1&#x3b2; expression, NF-&#x3ba;B, ROS, mitochondrial damage, lysosomal rupture, (p)JNK, ASC, NLRP3, neutrophils recruitment, IL-1&#x3b2;, caspase-1, IL-6, MCP-1</td>
<td rowspan="4" align="left">
<xref ref-type="bibr" rid="B16">Hsieh et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">J774A.1 &#x2b; LPS &#x2b; MSU</td>
</tr>
<tr>
<td align="left">THP-1 &#x2b; LPS &#x2b; MSU</td>
</tr>
<tr>
<td align="left">BMDM &#x2b; LPS &#x2b; MSU</td>
</tr>
<tr>
<td rowspan="2" align="left">
<italic>Chrysanthemum indicum</italic> L. (CI)</td>
<td align="left">C57BL6 mice &#x2b; MSU</td>
<td rowspan="2" align="left">&#x2193; IL-1&#x3b2;, caspase-1, ASC, neutrophils recruitment</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B55">Yu et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">BMDM &#x2b; LPS &#x2b; nigericin</td>
</tr>
<tr>
<td rowspan="2" align="left">
<italic>Cichorium intybus</italic> L. (CIL)</td>
<td align="left">SD rat &#x2b; MSU</td>
<td rowspan="2" align="left">&#x2193; Swelling degree, skin temperature, IL-1&#x3b2;, NF-&#x3ba;B, pI&#x3ba;B&#x3b1;, NLRP3, (p)p65</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B50">Wang et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">Rat macrophage</td>
</tr>
<tr>
<td rowspan="3" align="left">Huzhen Tongfeng (HZTF)</td>
<td align="left">SD rat &#x2b; MSU</td>
<td align="left">&#x2191; Antioxidant capacity</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B51">Wu et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">Raw 264.7 &#x2b; H2O2</td>
<td rowspan="2" align="left">&#x2193; Swelling degree, neutrophils infiltration, IL-1&#x3b2;, IL-6, TNF-&#x3b1;, ASC</td>
</tr>
<tr>
<td align="left">THP-1 &#x2b; MSU</td>
</tr>
<tr>
<td rowspan="3" align="left">Red ginseng (RG)</td>
<td align="left">C57BL6 mice &#x2b; MSU</td>
<td rowspan="3" align="left">&#x2193; IL-1&#x3b2;, ASC, NLRP3, caspase-1, neutrophils recruitment, IL-6, TNF-&#x3b1;, TGF-&#x3b2;</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B29">Lund et&#x20;al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">THP-1 &#x2b; LPS &#x2b; MSU</td>
</tr>
<tr>
<td align="left">Gout patients</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>
<italic>Mollugo pentaphylla</italic> L [Molluginaceae] (MP) is a component of an important traditional medicine in Taiwan which is used as an anticancer, antitoxic and diuretic agent. A previous study reported that MP suppressed inflammatory paw edema and pain in MSU-induced gout mice. In addition, MP showed anti-inflammatory activity by inhibiting the production of TNF-&#x3b1;, IL-1&#x3b2;, NLRP3 inflammasome and NF-&#x3ba;B (<xref ref-type="bibr" rid="B24">Lee et&#x20;al., 2017</xref>).</p>
<p>
<italic>Cinnamomum burmanni</italic> (Nees and T. Nees) Blume [Lauraceae] (CA) is known as a food or aroma. It has shown potential for antimicrobial activity <italic>in&#x20;vitro</italic>, and is used to treat diarrhea, lack of energy, and shortness of breath in traditional Chinese medicine. A previous research demonstrated that CA improved the survival rate of the LPS-induced septic shock mouse model and inhibited inflammasome activation including NLRP3, NLRC4, and AIM2, leading to suppression of interleukin-1&#x3b2; secretion. In addition, CA attenuated ASC oligomerization and its speck formation, and also enhanced the survival rates of both LPS induced septic shock and MSU-induced gout mice models (<xref ref-type="bibr" rid="B41">Shin et&#x20;al., 2017</xref>).</p>
<p>
<italic>Actinidia arguta</italic> (Siebold and Zucc.) Planch. ex Miq [Actinidiaceae] (AA) is known to have abundant nutrients, such as vitamins, polyphenols, etc. An existing study reported that AA regulated NLRP3 ubiquitination and ASC oligomerization, leading to the inhibition of NLRP3&#x20;inflammasome-mediated IL-1&#x3b2; secretion in the MSU-induced gout mice model (<xref ref-type="bibr" rid="B15">Heo et&#x20;al., 2018</xref>).</p>
<p>Taiwanese green propolis (TGP), a type of Taiwanese propolis, is known for its various beneficial biological functions, such as anticancer, anti-inflammatory, antifibrosis, antimicrobial, and antioxidant activities. In a prior study, TGP attenuated the peritoneal recruitment of neutrophils, and the levels of IL-1&#x3b2;, active caspase-1, IL-6 and MCP-1 in lavage fluids in the MSU-induced gout mice model. In addition, TGP inhibited pro IL-1&#x3b2; expression by reducing NF-&#x3ba;B activation and ROS production in LPS-activated macrophages. TGP also suppressed the activation signal by reducing mitochondrial damage, ROS production, lysosomal rupture, c-Jun N-terminal kinases 1/2 phosphorylation and ASC oligomerization. Furthermore, TGP inhibited the NLRP3 inflammasome partially via autophagy induction (<xref ref-type="bibr" rid="B16">Hsieh et&#x20;al., 2019</xref>).</p>
<p>
<italic>Chrysanthemum indicum</italic> L [Asteraceae] (CI) is a plant commonly used for food, tea and aroma. A previous study showed CI inhibited activation of NLRP3 and AIM2 inflammasomes, leading to suppression of IL-1&#x3b2; secretion <italic>in&#x20;vitro</italic>. In addition, CI regulated the phosphorylation of ASC, and also suppressed secretion of proinflammatory cytokines and neutrophils recruitment in the MSU-induced mice peritonitis model (<xref ref-type="bibr" rid="B55">Yu et&#x20;al., 2019</xref>).</p>
<p>
<italic>Cichorium intybus</italic> L [Asteraceae], known as chicory, is a perennial herbaceous plant of the daisy family Asteraceae. It is commonly used as a coffee substitute and food additive. In particular, chicory is also a major crop for extracting inulin, a natural polysaccharide. In a previous research, <italic>Cichorium intybus</italic> L. leaves (CIL) improved the swelling degree, inflammatory activity, and histopathological lesion in MSU-injected rat ankles. In addition, CIL decreased IL-1&#x3b2; secretion by suppressing the NF-&#x3ba;B and NLRP3 signaling pathways. Similar to the <italic>in vivo</italic> results, IL-1&#x3b2; release was also inhibited by CIL and chicoric acid, a specific effective compound in <italic>Cichorium intybus</italic> L, through the NF-&#x3ba;B and NLRP3 signaling pathways (<xref ref-type="bibr" rid="B50">Wang et&#x20;al., 2019</xref>).</p>
<p>Huzhen Tongfeng Formula (HZTF) is a compound extract from four Chinese medical herbs: Polygoni Cuspidati Rhizoma et Radix (PCRR, the root and rhizome of <italic>Polygonum cuspidatum</italic> Siebold. et Zucc [Polygonaceae]), Ligustri Lucidi Fructus (LLF, the fruit of <italic>Ligustrum lucidum</italic> W.T.Aiton [Oleaceae]), Herba Plantaginis [HP, the dried whole grass of <italic>Plantago asiatica</italic> L (Plantaginaceae)], and Nidus Vespae [NV, the honeycomb of Polistes olivaceus (De Geer)], Polistes Japonicus de Saussure, or Parapolybiavaria Fabricius). HZTF is used for gouty arthritis in Chinese traditional medicine. A previous study reported that HZTF suppressed paw swelling and neutrophil infiltration in intra-articular MSU-induced gout rats. HZTF also showed inhibited inflammatory cytokines (IL-1&#x3b2;, IL-6, and TNF-&#x3b1;) secretion in MSU-induced THP-1 cells and could prevent the oligomerization of ASC. Moreover, HZTF also demonstrated antioxidant capacity in cell-free and cell-base tests (<xref ref-type="bibr" rid="B51">Wu et&#x20;al., 2019</xref>).</p>
<p>Red ginseng [RG, <italic>Panax ginseng</italic> C.A.Mey (Araliaceae)] is known to have various effects such as immunity improvement, fatigue relief, memory improvement, blood circulation improvement, antioxidation, mitigation of menopausal women&#x2019;s symptoms, and anticancer. Such effects have been reported in basic experimental research as well as clinical study. In a previous study, RG lowered the number of WBCs in the lavage fluid leading to suppress acute gout inflammation in the air-pouch mice model. Also, RG inhibited MSU-induced IL-1&#x3b2; production in THP-1 cells. The assembly of NLRP3 inflammasomes was inhibited via reduced ASC expression and oligomerization. Furthermore, RG treatment for 3&#x20;months in patients showed reduced NLRP3 expression compared to baseline (<xref ref-type="bibr" rid="B29">Lund et&#x20;al., 2021</xref>).</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>Gout is the most common form of inflammatory arthritis worldwide. The risk of gout increases with age and is therefore more common in an aging population. Allopurinol or Febuxostat has been used as treatment for gout which has been traditionally administered to lower uric acid levels. However, such traditional therapy is difficult to conduct in patients with certain underlying diseases or for long-term periods due to the risk of side effects. Previous animal model studies using anakinra (IL-1R antagonist) suggested the possibility of targeting IL-1&#x3b2; to modulate MSU-induced inflammation (<xref ref-type="bibr" rid="B30">Martin et&#x20;al., 2009</xref>; <xref ref-type="bibr" rid="B48">Torres et&#x20;al., 2009</xref>), and early clinical studies also demonstrated efficacy in the treatment of acute and chronic gout patients (<xref ref-type="bibr" rid="B34">Mcgonagle et&#x20;al., 2007</xref>; <xref ref-type="bibr" rid="B43">So et&#x20;al., 2007</xref>; <xref ref-type="bibr" rid="B33">McGonagle et&#x20;al., 2008</xref>). With the increased understanding of the pathophysiology of gout, new methods of gout treatment in relation to the inflammatory process have been introduced. A previous study also showed that caffeic acid, <italic>&#x3b2;</italic>-carotene and sulforaphane modulate inflammation by acting as selective and direct inhibitors of the NLRP3 inflammasome in MSU-induced gout mice (<xref ref-type="bibr" rid="B23">Lee et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B54">Yang et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B53">Yang et&#x20;al., 2020</xref>). This could be evidence of a new pharmacological strategy of anti-NLRP3 inflammasome activators in the prevention and treatment of gout&#x20;onset.</p>
<p>Various studies have been conducted on natural products that inhibit gout by targeting the NLRP3 inflammasome. In this report, studies of on natural extracts using animal models over the past 5&#xa0;years were summarized and presented. Such an overview suggests that the use of natural products acting at various stages of NLRP3 signaling may be a suitable pharmacological approach for the management of acute and chronic&#x20;gout.</p>
<p>However, despite great advances in our understanding of the inflammatory processes associated with gout, various issues still remain to be addressed. While the exact mechanism by which MSU crystals are recognized by immune cells remains elusive, the role of other cytokines that may be activated by the NLRP3 inflammasome, such as IL-18, must also be considered. In addition, MSU can induce inflammatory responses through pathways other than the NLRP3 inflammasome. Thus, it is important to identify these pathways and understand their interactions with the NLRP3 inflammasome and IL-1&#x3b2; production during the development and resolution phases of gout. Understanding such mechanisms offers us new opportunities to disrupt the inflammatory pathway and anticipate the development of more effective treatments for gout. Therefore, further research on natural products and their regulation of NLRP3 inflammasome assembly in a wide range of gout is needed to elucidate various pharmacological mechanisms and develop effective gout therapeutics.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Author Contributions</title>
<p>GY and JL contributed for the literature research, writing, and editing of the manuscript. GY, HJK, and HSK. conceptualized&#x20;and finalized Figures and a Table. JL and HJK. contributed to the project administration and funding&#x20;acquisition. HJK and JL supervised and contributed to the manuscript revision and editing. All authors have read and agreed to the published&#x20;version of the manuscript.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This study was supported by a grant of the Korea Health Technology R&#x26;D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HF20C0145) and National Research Foundation of Korea (NRF) (NRF-2020R1I1A3072176 and NRF-2017R1A6A3A11032822) funded by the Korean government (Ministry of Science, ICT and Future Planning) and Woosuk University. HJK is supported by Intramural Research Program of WOOSUK University.</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amaral</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>V. V.</given-names>
</name>
<name>
<surname>Tavares</surname>
<given-names>L. D.</given-names>
</name>
<name>
<surname>Sachs</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Coelho</surname>
<given-names>F. M.</given-names>
</name>
<name>
<surname>Fagundes</surname>
<given-names>C. T.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>NLRP3&#x20;Inflammasome-Mediated Neutrophil Recruitment and Hypernociception Depend on Leukotriene B(4) in a Murine Model of Gout</article-title>. <source>Arthritis Rheum.</source> <volume>64</volume>, <fpage>474</fpage>&#x2013;<lpage>484</lpage>. <pub-id pub-id-type="doi">10.1002/art.33355</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauernfeind</surname>
<given-names>F. G.</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Stutz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alnemri</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Speert</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Cutting Edge: NF-kappaB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression</article-title>. <source>J.&#x20;Immunol.</source> <volume>183</volume>, <fpage>787</fpage>&#x2013;<lpage>791</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0901363</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassel</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Eisenbarth</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Sadler</surname>
<given-names>J.&#x20;J.</given-names>
</name>
<name>
<surname>Colegio</surname>
<given-names>O. R.</given-names>
</name>
<name>
<surname>Tephly</surname>
<given-names>L. A.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>The Nalp3 Inflammasome Is Essential for the Development of Silicosis</article-title>. <source>Proc. Natl. Acad. Sci. U S A.</source> <volume>105</volume>, <fpage>9035</fpage>&#x2013;<lpage>9040</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0803933105</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>J.&#x20;H.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>J.&#x20;Y.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Historical Study of the Etymological Form and Translational Process of Gout (Tongfeng,)</article-title>. <source>Uisahak</source> <volume>24</volume>, <fpage>533</fpage>&#x2013;<lpage>557</lpage>. <pub-id pub-id-type="doi">10.13081/kjmh.2015.24.533</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalbeth</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Terkeltaub</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kopicko</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bhakta</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat in Patients with Tophaceous Gout: Findings of a Phase III Clinical Trial</article-title>. <source>Arthritis Rheumatol.</source> <volume>69</volume>, <fpage>1903</fpage>&#x2013;<lpage>1913</lpage>. <pub-id pub-id-type="doi">10.1002/art.40159</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dehlin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jacobsson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Roddy</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Global Epidemiology of Gout: Prevalence, Incidence, Treatment Patterns and Risk Factors</article-title>. <source>Nat. Rev. Rheumatol.</source> <volume>16</volume>, <fpage>380</fpage>&#x2013;<lpage>390</lpage>. <pub-id pub-id-type="doi">10.1038/s41584-020-0441-1</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dostert</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>P&#xe9;trilli</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Van Bruggen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Steele</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mossman</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Tschopp</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Innate Immune Activation through Nalp3 Inflammasome Sensing of Asbestos and Silica</article-title>. <source>Science</source> <volume>320</volume>, <fpage>674</fpage>&#x2013;<lpage>677</lpage>. <pub-id pub-id-type="doi">10.1126/science.1156995</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elliott</surname>
<given-names>E. I.</given-names>
</name>
<name>
<surname>Sutterwala</surname>
<given-names>F. S.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Initiation and Perpetuation of NLRP3 Inflammasome Activation and Assembly</article-title>. <source>Immunol. Rev.</source> <volume>265</volume>, <fpage>35</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12286</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes-Alnemri</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sagara</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Alnemri</surname>
<given-names>E. S.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Cutting Edge: TLR Signaling Licenses IRAK1 for Rapid Activation of the NLRP3 Inflammasome</article-title>. <source>J.&#x20;Immunol.</source> <volume>191</volume>, <fpage>3995</fpage>&#x2013;<lpage>3999</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1301681</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franchi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kanneganti</surname>
<given-names>T. D.</given-names>
</name>
<name>
<surname>Dubyak</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Differential Requirement of P2X7 Receptor and Intracellular K&#x2b; for Caspase-1 Activation Induced by Intracellular and Extracellular Bacteria</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>282</volume>, <fpage>18810</fpage>&#x2013;<lpage>18818</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M610762200</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yune</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Bee Venom Alleviated Edema and Pain in Monosodium Urate Crystals-Induced Gouty Arthritis in Rat by Inhibiting Inflammation</article-title>. <source>Toxins (Basel)</source> <volume>13</volume>, <fpage>661</fpage>. <pub-id pub-id-type="doi">10.3390/toxins13090661</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gutman</surname>
<given-names>A. B.</given-names>
</name>
</person-group> (<year>1973</year>). <article-title>The Past Four Decades of Progress in the Knowledge of Gout, with an Assessment of the Present Status</article-title>. <source>Arthritis Rheum.</source> <volume>16</volume>, <fpage>431</fpage>&#x2013;<lpage>445</lpage>. <pub-id pub-id-type="doi">10.1002/art.1780160402</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2016a</year>). <article-title>Mechanism and Regulation of NLRP3 Inflammasome Activation</article-title>. <source>Trends Biochem. Sci.</source> <volume>41</volume>, <fpage>1012</fpage>&#x2013;<lpage>1021</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2016.09.002</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Motro</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2016b</year>). <article-title>NEK7 Is an Essential Mediator of NLRP3 Activation Downstream of Potassium Efflux</article-title>. <source>Nature</source> <volume>530</volume>, <fpage>354</fpage>&#x2013;<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1038/nature16959</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heo</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Koppula</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S. H.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Actinidia Arguta Extract Attenuates Inflammasome Activation: Potential Involvement in NLRP3 Ubiquitination</article-title>. <source>J.&#x20;Ethnopharmacol</source> <volume>213</volume>, <fpage>159</fpage>&#x2013;<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2017.11.023</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsieh</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>Y. K.</given-names>
</name>
<name>
<surname>Ju</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Nai</surname>
<given-names>Y. S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. W.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Mechanistic Insight into the Attenuation of Gouty Inflammation by Taiwanese green Propolis via Inhibition of the NLRP3 Inflammasome</article-title>. <source>J.&#x20;Cel Physiol</source> <volume>234</volume>, <fpage>4081</fpage>&#x2013;<lpage>4094</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.27204</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joosten</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Netea</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Mylona</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Koenders</surname>
<given-names>M. I.</given-names>
</name>
<name>
<surname>Malireddi</surname>
<given-names>R. K.</given-names>
</name>
<name>
<surname>Oosting</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Engagement of Fatty Acids with Toll-like Receptor 2 Drives Interleukin-1&#x3b2; Production via the ASC/caspase 1 Pathway in Monosodium Urate Monohydrate crystal-induced Gouty Arthritis</article-title>. <source>Arthritis Rheum.</source> <volume>62</volume>, <fpage>3237</fpage>&#x2013;<lpage>3248</lpage>. <pub-id pub-id-type="doi">10.1002/art.27667</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juliana</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fernandes-Alnemri</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Farias</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Alnemri</surname>
<given-names>E. S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Non-transcriptional Priming and Deubiquitination Regulate NLRP3 Inflammasome Activation</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>287</volume>, <fpage>36617</fpage>&#x2013;<lpage>36622</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.407130</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamkanfi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dixit</surname>
<given-names>V. M.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Inflammasomes and Their Roles in Health and Disease</article-title>. <source>Annu. Rev. Cel Dev Biol</source> <volume>28</volume>, <fpage>137</fpage>&#x2013;<lpage>161</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-cellbio-101011-155745</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamkanfi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dixit</surname>
<given-names>V. M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Mechanisms and Functions of Inflammasomes</article-title>. <source>Cell</source> <volume>157</volume>, <fpage>1013</fpage>&#x2013;<lpage>1022</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.04.007</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landis</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Haskard</surname>
<given-names>D. O.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Pathogenesis of crystal-induced Inflammation</article-title>. <source>Curr. Rheumatol. Rep.</source> <volume>3</volume>, <fpage>36</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1007/s11926-001-0049-7</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landis</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Yagnik</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Florey</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Philippidis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Emons</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>J.&#x20;C.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Safe Disposal of Inflammatory Monosodium Urate Monohydrate Crystals by Differentiated Macrophages</article-title>. <source>Arthritis Rheum.</source> <volume>46</volume>, <fpage>3026</fpage>&#x2013;<lpage>3033</lpage>. <pub-id pub-id-type="doi">10.1002/art.10614</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H. E.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>N. D.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>J.&#x20;Y.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Targeting ASC in NLRP3 Inflammasome by Caffeic Acid Phenethyl Ester: a Novel Strategy to Treat Acute Gout</article-title>. <source>Sci. Rep.</source> <volume>6</volume>, <fpage>38622</fpage>. <pub-id pub-id-type="doi">10.1038/srep38622</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Shon</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>O. S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D. S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Effects of Mollugo Pentaphylla Extract on Monosodium Urate crystal-induced Gouty Arthritis in Mice</article-title>. <source>BMC Complement. Altern. Med.</source> <volume>17</volume>, <fpage>447</fpage>. <pub-id pub-id-type="doi">10.1186/s12906-017-1955-1</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Troutman</surname>
<given-names>T. D.</given-names>
</name>
<name>
<surname>Jennings</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brewer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>IRAK-1 Bypasses Priming and Directly Links TLRs to Rapid NLRP3 Inflammasome Activation</article-title>. <source>Proc. Natl. Acad. Sci. U S A.</source> <volume>111</volume>, <fpage>775</fpage>&#x2013;<lpage>780</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1320294111</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu-Bryan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sydlaske</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Terkeltaub</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Innate Immunity Conferred by Toll-like Receptors 2 and 4 and Myeloid Differentiation Factor 88 Expression Is Pivotal to Monosodium Urate Monohydrate crystal-induced Inflammation</article-title>. <source>Arthritis Rheum.</source> <volume>52</volume>, <fpage>2936</fpage>&#x2013;<lpage>2946</lpage>. <pub-id pub-id-type="doi">10.1002/art.21238</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez-Castejon</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Luheshi</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Compan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>High</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Whitehead</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Flitsch</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Deubiquitinases Regulate the Activity of Caspase-1 and Interleukin-1&#x3b2; Secretion via Assembly of the Inflammasome</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>288</volume>, <fpage>2721</fpage>&#x2013;<lpage>2733</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.422238</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Magupalli</surname>
<given-names>V. G.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Atianand</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>M. R.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Unified Polymerization Mechanism for the Assembly of ASC-dependent Inflammasomes</article-title>. <source>Cell</source> <volume>156</volume>, <fpage>1193</fpage>&#x2013;<lpage>1206</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.02.008</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lund</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Rehkopf</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Sokolow</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Sam</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Jouanard</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Schacht</surname>
<given-names>A. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Land Use Impacts on Parasitic Infection: a Cross-Sectional Epidemiological Study on the Role of Irrigated Agriculture in Schistosome Infection in a Dammed Landscape</article-title>. <source>Infect. Dis. Poverty</source> <volume>10</volume>, <fpage>35</fpage>. <pub-id pub-id-type="doi">10.1186/s40249-021-00816-5</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Walton</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Resident Macrophages Initiating and Driving Inflammation in a Monosodium Urate Monohydrate crystal-induced Murine Peritoneal Model of Acute Gout</article-title>. <source>Arthritis Rheum.</source> <volume>60</volume>, <fpage>281</fpage>&#x2013;<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1002/art.24185</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinon</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>P&#xe9;trilli</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mayor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tardivel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tschopp</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Gout-associated Uric Acid Crystals Activate the NALP3 Inflammasome</article-title>. <source>Nature</source> <volume>440</volume>, <fpage>237</fpage>&#x2013;<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1038/nature04516</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masumoto</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Taniguchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ayukawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sarvotham</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kishino</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Niikawa</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>1999</year>). <article-title>ASC, a Novel 22-kDa Protein, Aggregates during Apoptosis of Human Promyelocytic Leukemia HL-60 Cells</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>274</volume>, <fpage>33835</fpage>&#x2013;<lpage>33838</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.48.33835</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mcgonagle</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Madden</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Emery</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mcdermott</surname>
<given-names>M. F.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Successful Treatment of Resistant Pseudogout with Anakinra</article-title>. <source>Arthritis Rheum.</source> <volume>58</volume>, <fpage>631</fpage>&#x2013;<lpage>633</lpage>. <pub-id pub-id-type="doi">10.1002/art.23119</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mcgonagle</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Shankaranarayana</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Madden</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Emery</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mcdermott</surname>
<given-names>M. F.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Management of Treatment Resistant Inflammation of Acute on Chronic Tophaceous Gout with Anakinra</article-title>. <source>Ann. Rheum. Dis.</source> <volume>66</volume>, <fpage>1683</fpage>&#x2013;<lpage>1684</lpage>. <pub-id pub-id-type="doi">10.1136/ard.2007.073759</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mu&#xf1;oz-Planillo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kuffa</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mart&#xed;nez-Col&#xf3;n</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Rajendiran</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>K&#x207a; Efflux Is the Common Trigger of NLRP3 Inflammasome Activation by Bacterial Toxins and Particulate Matter</article-title>. <source>Immunity</source> <volume>38</volume>, <fpage>1142</fpage>&#x2013;<lpage>1153</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2013.05.016</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>P&#xe9;trilli</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Papin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dostert</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mayor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martinon</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tschopp</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Activation of the NALP3 Inflammasome Is Triggered by Low Intracellular Potassium Concentration</article-title>. <source>Cell Death Differ</source> <volume>14</volume>, <fpage>1583</fpage>&#x2013;<lpage>1589</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cdd.4402195</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saag</surname>
<given-names>K. G.</given-names>
</name>
<name>
<surname>Fitz-Patrick</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kopicko</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bhakta</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Lesinurad Combined with Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients with an Inadequate Response to Standard-Of-Care Allopurinol (A US-Based Study)</article-title>. <source>Arthritis Rheumatol.</source> <volume>69</volume>, <fpage>203</fpage>&#x2013;<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1002/art.39840</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seok</surname>
<given-names>J.&#x20;K.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.&#x20;Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Regulation of the NLRP3 Inflammasome by Post-Translational Modifications and Small Molecules</article-title>. <source>Front. Immunol.</source> <volume>11</volume>, <fpage>618231</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.618231</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharif</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Magupalli</surname>
<given-names>V. G.</given-names>
</name>
<name>
<surname>Andreeva</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Structural Mechanism for NEK7-Licensed Activation of NLRP3 Inflammasome</article-title>. <source>Nature</source> <volume>570</volume>, <fpage>338</fpage>&#x2013;<lpage>343</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1295-z</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shim</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K. H.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Posttranslational Regulation of the NLR Family Pyrin Domain-Containing 3 Inflammasome</article-title>. <source>Front. Immunol.</source> <volume>9</volume>, <fpage>1054</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.01054</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shin</surname>
<given-names>W. Y.</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Koppula</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S. H.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Protective Effects of Cinnamomum cassia (Lamaceae) against Gout and Septic Responses via Attenuation of Inflammasome Activation in Experimental Models</article-title>. <source>J.&#x20;Ethnopharmacol</source> <volume>205</volume>, <fpage>173</fpage>&#x2013;<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2017.03.043</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silvestre</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>P. J.&#x20;S.</given-names>
</name>
<name>
<surname>El-Shishtawy</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Natural Products as a Source for New Leads in Gout Treatment</article-title>. <source>Evid. Based Complement. Alternat Med.</source> <volume>2020</volume>, <fpage>8274975</fpage>. <pub-id pub-id-type="doi">10.1155/2020/8274975</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>So</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Smedt</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Revaz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tschopp</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>A Pilot Study of IL-1 Inhibition by Anakinra in Acute Gout</article-title>. <source>Arthritis Res. Ther.</source> <volume>9</volume>, <fpage>R28</fpage>. <pub-id pub-id-type="doi">10.1186/ar2143</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stutz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Monks</surname>
<given-names>B. G.</given-names>
</name>
<name>
<surname>Latz</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>ASC Speck Formation as a Readout for Inflammasome Activation</article-title>. <source>Methods Mol. Biol.</source> <volume>1040</volume>, <fpage>91</fpage>&#x2013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-62703-523-1_8</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutterwala</surname>
<given-names>F. S.</given-names>
</name>
<name>
<surname>Haasken</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cassel</surname>
<given-names>S. L.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Mechanism of NLRP3 Inflammasome Activation</article-title>. <source>Ann. N. Y Acad. Sci.</source> <volume>1319</volume>, <fpage>82</fpage>&#x2013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1111/nyas.12458</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swanson</surname>
<given-names>K. V.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ting</surname>
<given-names>J.&#x20;P.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The NLRP3 Inflammasome: Molecular Activation and Regulation to Therapeutics</article-title>. <source>Nat. Rev. Immunol.</source> <volume>19</volume>, <fpage>477</fpage>&#x2013;<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-019-0165-0</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Fransen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>T. L.</given-names>
</name>
<name>
<surname>Dalbeth</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Schumacher</surname>
<given-names>H. R.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout</article-title>. <source>Arthritis Care Res. (Hoboken)</source> <volume>67</volume>, <fpage>1304</fpage>&#x2013;<lpage>1315</lpage>. <pub-id pub-id-type="doi">10.1002/acr.22585</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torres</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Croll</surname>
<given-names>S. D.</given-names>
</name>
<name>
<surname>Reinhardt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dore</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Hyperalgesia, Synovitis and Multiple Biomarkers of Inflammation Are Suppressed by Interleukin 1 Inhibition in a Novel Animal Model of Gouty Arthritis</article-title>. <source>Ann. Rheum. Dis.</source> <volume>68</volume>, <fpage>1602</fpage>&#x2013;<lpage>1608</lpage>. <pub-id pub-id-type="doi">10.1136/ard.2009.109355</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsuchiya</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hosojima</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kushiyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mahib</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Gasdermin D Mediates the Maturation and Release of IL-1&#x3b1; Downstream of Inflammasomes</article-title>. <source>Cell Rep</source> <volume>34</volume>, <fpage>108887</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2021.108887</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Cichorium Intybus L. Extract Suppresses Experimental Gout by Inhibiting the NF-&#x39a;b and NLRP3 Signaling Pathways</article-title>. <source>Int. J.&#x20;Mol. Sci.</source> <volume>20</volume>. <pub-id pub-id-type="doi">10.3390/ijms20194921</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Z. C.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z. L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Suppressive Effect of Huzhentongfeng on Experimental Gouty Arthritis: An <italic>In Vivo</italic> and <italic>In Vitro</italic> Study</article-title>. <source>Evid. Based Complement. Alternat Med.</source> <volume>2019</volume>, <fpage>2969364</fpage>. <pub-id pub-id-type="doi">10.1155/2019/2969364</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yagnik</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Hillyer</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Smythe</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Krausz</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Haskard</surname>
<given-names>D. O.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>Noninflammatory Phagocytosis of Monosodium Urate Monohydrate Crystals by Mouse Macrophages. Implications for the Control of Joint Inflammation in Gout</article-title>. <source>Arthritis Rheum.</source> <volume>43</volume>, <fpage>1779</fpage>&#x2013;<lpage>1789</lpage>. <pub-id pub-id-type="doi">10.1002/1529-0131(200008)43:8&#x3c;1779::AID-ANR14&#x3e;3.0.CO;2-2</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. E.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Koh</surname>
<given-names>J.&#x20;H.</given-names>
</name>
<name>
<surname>Seok</surname>
<given-names>J.&#x20;K.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Direct Binding to NLRP3 Pyrin Domain as a Novel Strategy to Prevent NLRP3-Driven Inflammation and Gouty Arthritis</article-title>. <source>Arthritis Rheumatol.</source> <volume>72</volume>, <fpage>1192</fpage>&#x2013;<lpage>1202</lpage>. <pub-id pub-id-type="doi">10.1002/art.41245</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yeon</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. E.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Suppression of NLRP3 Inflammasome by Oral Treatment with Sulforaphane Alleviates Acute Gouty Inflammation</article-title>. <source>Rheumatology (Oxford)</source> <volume>57</volume>, <fpage>727</fpage>&#x2013;<lpage>736</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/kex499</pub-id> </citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Akther</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J.&#x20;H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>T. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Chrysanthemum Indicum Extract Inhibits NLRP3 and AIM2 Inflammasome Activation via Regulating ASC Phosphorylation</article-title>. <source>J.&#x20;Ethnopharmacol</source> <volume>239</volume>, <fpage>111917</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2019.111917</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>